Pulmonary Fibrosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Fibrosis stocks.

Pulmonary Fibrosis Stocks Recent News

Date Stock Title
May 17 BIIB Ionis, Biogen Down on Ending Development of ALS Drug
May 17 BIIB Ionis (IONS), Biogen Down on Ending Development of ALS Drug
May 16 BIIB Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 BIIB Biogen and Ionis drop ALS candidate after trial setback
May 16 BIIB Biogen, Ionis shelve ALS drug following study failure
May 16 OCEA Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
May 16 BIIB REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16 BIIB Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 15 HCWB HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
May 15 BIIB Eisai projects major growth for Alzheimer's therapy Leqembi
May 15 BIIB Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15 BIIB Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15 BIIB Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15 RVPH Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
May 15 BIIB Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy
May 15 BIIB UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 BIIB Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14 BIIB Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 RVPH Reviva Pharmaceuticals GAAP EPS of -$0.25
Pulmonary Fibrosis

Pulmonary fibrosis is a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer.Causes include environmental pollution, certain medications, connective tissue diseases, infections (including SARS infections), interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF), an interstitial lung disease of unknown cause, is most common. Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests.There is no cure and there are limited treatment options available. Treatment is directed towards efforts to improve symptoms and may include oxygen therapy and pulmonary rehabilitation. Certain medications may be used to try to slow the worsening of scarring. Lung transplantation may occasionally be an option. At least 5 million people are affected globally. Life expectancy is generally less than five years.

Browse All Tags